Metastatic Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORI

Metastatic Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 85+ Metastatic Prostate Cancer treatment therapies, analyzes DelveInsight.

Metastatic Prostate Cancer Overview:

Metastatic prostate cancer is an advanced stage of the disease where cancer cells from the prostate gland spread to other parts of the body, often through the bloodstream or lymphatic system. It poses a significant clinical challenge as it can affect vital organs like bones, lymph nodes, liver, and lungs. Common symptoms include bone pain (especially in the lower back, hips, or ribs), urinary issues, erectile dysfunction, fatigue, weight loss, and, in severe cases, neurological problems due to spinal cord compression.

The development of metastatic prostate cancer is influenced by factors such as age, family history, ethnicity, and genetics. While the exact cause is unclear, the disease typically originates from prostate gland cells and progresses gradually. As it advances, cancer cells can spread, with bones being a primary site of metastasis, leading to severe pain and skeletal complications.

Request for a detailed insights report on Metastatic Prostate Cancer pipeline insights @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Metastatic Prostate Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Prostate Cancer Therapeutics Market.

Key Takeaways from the Metastatic Prostate Cancer Pipeline Report

DelveInsight's Metastatic Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial of Cabometyx® and atezolizumab in mCRPC showed a minor, non-significant improvement in overall survival but achieved its progression-free survival (PFS) goal.
That same month, Foundation Medicine secured FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
In July 2024, the ARANOTE trial demonstrated that NUBEQA® combined with ADT significantly enhanced radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
Also in July 2024, the FDA granted fast-track status to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals received FDA approval to conduct a Phase II/III trial of KPG-121 in combination with Abiraterone for mCRPC.
In May 2024, Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial to evaluate FPI-2265 in mCRPC patients.
In April 2024, Astellas Pharma gained European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
That same month, FibroGen shared positive Phase 1 trial results for FG-3246 in mCRPC.
On November 16, 2023, the FDA approved enzalutamide (Xtandi) for high-risk biochemical recurrent non-metastatic castration-sensitive prostate cancer (nmCSPC).
Key Metastatic Prostate Cancer companies such as Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4, Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development, LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc, ValiRx Plc, Epizyme, Inc., Astrazeneca, and others are evaluating new drugs for Metastatic Prostate Cancer to improve the treatment landscape.
Promising Metastatic Prostate Cancer pipeline therapies in various stages of development include TAVT-45, Onvansertib, ONCT-534, VIO-01, ORIC-944, and others.

Metastatic Prostate Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Prostate Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Prostate Cancer market.

Download our free sample page report on Metastatic Prostate Cancer pipeline insights @ https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Prostate Cancer Emerging Drugs

TAVT-45: Tavanta Therapeutics
Onvansertib: Cardiff Oncology
ONCT-534: Oncternal Therapeutics
VIO-01: Valerio Therapeutics
ORIC-944: ORIC Pharmaceuticals

Metastatic Prostate Cancer Companies

Around 80 key companies are currently developing therapies for metastatic prostate cancer. Among them, Tavanta Therapeutics has a drug candidate in the most advanced stage before Phase III.

DelveInsight's report covers around 85+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Metastatic Prostate Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Prostate Cancer Therapies and Key Companies: Metastatic Prostate Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Prostate Cancer Pipeline Therapeutic Assessment
• Metastatic Prostate Cancer Assessment by Product Type
• Metastatic Prostate Cancer By Stage
• Metastatic Prostate Cancer Assessment by Route of Administration
• Metastatic Prostate Cancer Assessment by Molecule Type

Download Metastatic Prostate Cancer Sample report to know in detail about the Metastatic Prostate Cancer treatment market @ Metastatic Prostate Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Metastatic Prostate Cancer Current Treatment Patterns
4. Metastatic Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Prostate Cancer Late-Stage Products (Phase-III)
7. Metastatic Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Prostate Cancer Discontinued Products
13. Metastatic Prostate Cancer Product Profiles
14. Metastatic Prostate Cancer Key Companies
15. Metastatic Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Metastatic Prostate Cancer Unmet Needs
18. Metastatic Prostate Cancer Future Perspectives
19. Metastatic Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Prostate Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.